Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 12/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224549 | 0.87 | TAAR1 (0.70) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL7321875 | 0.86 | TAAR1 (0.45) | TAAR1HTR2AGABRA1GABRB2 | |
| SCHEMBL3057797 | 0.85 | TAAR1 (0.60) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL6546730 | 0.84 | GABRA1 (0.50) | TAAR1GABRA1GABRB2 | |
| Ethylamine SCHEMBL28337086 | 0.84 | GABRA1 (0.50) | TAAR1GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL14157333 | 0.83 | TAAR1 (0.58) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL3067170 | 0.81 | TAAR1 (0.56) | TAAR1HTR2AHRH1 | |
| Methylamine SCHEMBL27540110 | 0.81 | GABRA1 (0.52) | TAAR1GABRA1GABRB2 | |
| SCHEMBL25425763 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2 | |
| SCHEMBL36294 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-20210069188-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2021-03-11 | — | — | US | disclosed |
| EP-3130596-B1 | GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE | UNIV HIROSAKI (JP) | 2021-01-20 | — | — | EP | disclosed |
| EP-3130596-A1 | NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE | Hirosaki University (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9320786-B2 | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140079736-A1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-03-20 | — | — | US | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| WO-2012170554-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | KAMENECKA THEODORE MARK (US) | 2012-12-13 | — | — | WO | disclosed |
| US-6916806-B2 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-5536853-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | TAAR1 173/4885HTR2A 206/4885HRH1 8/4885 |
| US-20140079736-A1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | CLIC1, SLC47A2, SLC47A1 | TAAR1 3118/4885HTR2A 3741/4885HRH1 1413/4885 |
| US-20210069188-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN2, PTPN5, PTPRJ | TAAR1 4128/4885HTR2A 2235/4885HRH1 3856/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | TAAR1 1120/4885HTR2A 3742/4885HRH1 2644/4885 |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | TAAR1 99/4885HTR2A 8/4885HRH1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.